$1.59
-0.04-2.45%
Últ. Act.: Oct 23, 4:45 PM
Inhibikase Therapeutics (IKT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.09 | $-0.10 | $-0.12 | $-0.12 |
| Actual | $-0.11 | $-0.10 | $-0.10 | $-0.13 |
| Surprise | -22.2% | 0.00% | +16.7% | -8.33% |
| Revenue | ||||
| Estimate | — | — | — | — |
| Actual | $0 | $0 | $0 | — |
| Surprise | — | — | — | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.12 | $-0.12 | $-0.11 | $-0.13 |
| Revenue | ||||
| Consensus | — | $187500 | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $-0.11 | $-0.09 | -22.2 % |
| Q1 | May 12, 2026 | $-0.10 | $-0.10 | 0.00 % |
| Q4 | Mar 26, 2026 | $-0.10 | $-0.12 | 16.7 % |
| Q3 | Nov 14, 2025 | $-0.13 | $-0.12 | -8.33 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 14, 2022 | $7.29K | $200.00K | -96.4 % |
| Q2 | Aug 12, 2022 | $6.55K | $300.00K | -97.8 % |
| Q1 | May 16, 2022 | $46.03K | $300.00K | -84.7 % |
| Q4 | Mar 31, 2022 | $1.94M | $300.00K | 548.0 % |